p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma: A comparative analysis with clinico-pathological factors

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 7, 1997, Pages 388-394

  Gunther T ^a   Schneider Stock, R ^a   Rys J ^b   Niezabitowski, A ^b   Roessner, A ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast carcinoma; mdm2; p53; p53 gene mutation

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; CODON; CYTOMETRY; DIPLOIDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PLOIDIES; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030762728     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050076     Document Type: Article

References (45)

1. Bártek J, Bártkova J, Vojtèšek B, Stašková Z, Rejthar A, Kovarik J, Lane DP (1990a) Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839-844
2. Bártek J, Iggo R, Gannon J, Lane DP (1990b) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893-899
3. Bloom HJG, Richardson WW (1957) Histologic grading and prognosis in breast cancer. Br J Cancer 11:359-377
4. Bosari s, Lee AKC, Viale G, Heatley GJ, Coggi G (1992) Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch [A] 421:291-295
5. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF (1994) p53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147-2156
6. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988) P53 expression in breast cancer. Int J Cancer 41:178-183
7. Cornelis RS, Vliet M van, Vos CBJ (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200-4206
8. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR (1991) Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88:5006-5010
9. Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP 70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439
10. Domagala W, Mariewski M, Kubiak R, Bartkowiak J, Osborn M (1993) Immunhistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch [A] 423:497-502
11. Dunn JM, Hastrich DJ, Newcomb P, Webb JCJ, Maitland NJ, Farndon JR (1993) Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg 80:1410-1412
12. Elston CW, Ellis IO (1991), Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403-410
13. Fisher CJ, Gillett CE, Vojtéšek B, Barnes DM, Millis RR (1994) Problems with p53 immunhistochemical staining. The effect of fixation and variation in the methods of evaluation. Br J Cancer 69:26-31
14. Goldmann D, Merril CR (1982) Silver staining of DNA in polyacrylamide gels: linearity and effect of fragment size. Electrophoresis 3:24-26
15. Hermanek P, Scheibe O, Spiessl B, Wagner G (1987) TNM-Klassifikation maligner Tumoren (UICC) 4. Springer. Berlin Heidelberg New York
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
17. Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114
18. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S (1991) Nuclear p53 immunreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840
19. Jacquemier J, Molès JP, Penault-Llorca F, Adèlaide J, Torrente M, Viens P, Birnbaum D, Theillet C (1994) p53 immunhistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69:846-852
20. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H (1994) Nuclear Immunoreaction of p53 protein in soft tissue sarcomas. Cancer 73:2499-2505
21. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
22. Lane DP, Benchimol S (1990) p53: oncogene or antioncogene? Genes Dev 4:1-8
23. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453-456
24. Lohmann D, Ruhri Ch, Schmitt M, Graeff H, Höfler H (1993) Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurence of false-positives and false-negatives. Diagn Mol Pathol 2:36-41
25. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglionis C, Bevilacqua G, Barbareschi M (1995a) mdm 2 gene alterations and mdm 2 protein expression in breast carcinomas. J Pathol 175:31-38
26. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G (1995b) mdm 2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4:93-97
27. Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type-p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013-5020
28. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
29. Montenarh M (1992) Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. Crit Rev Onco 3:233-256
30. NIH Consensus Conference (1991) Treatment of early-stage breast cancer. JAMA 265:391-395
31. Oliner JD, Kinzler KW, Melzer PS, George D, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
32. Orita M, Suzuki Y, Sekyia T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics 5:874-879
33. Poller DN, Roberts EC, Bell JA, Elston CW, Balmey RW, Ellis IO (1993) P53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24:463-468
34. Remmele W (1986) Mammakarzinom: Prognostisch wichtige Rezeptorbestimmungen. Dtsch Ärztebl 83:3359-3362
35. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning - a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
36. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, Kovach JS (1992) Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 84:246-252
37. Takahashi K, Suzuki K (1994) DNA synthesis-associated nuclear exclusion of p53 in normal human breast epithelial cells in culture. Ongogene 9:183-188
38. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM (1992) p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50:528-532
39. Thor AD, Yandell DW (1993) Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J Natl Cancer Inst 85:176-177
40. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S (1993) p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84:394-401
41. Varley JM, Brammer WJ, Lane DP, Swallow JE, Dolan C, Walker RA (1991) Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413-421
42. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70:523-526
43. Vojtesek B, Bàrtek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 152:237-244
44. Walker RA, Dearing SJ, Lane DP, Varley JM (1991) Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165:203-211
45. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79